Abstract
The US Department of Health and Human Services (DHHS) recently incorporated the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) into clinical treatment guidelines for patients with HIV. DTG/3TC has the potential to reduce lifelong drug exposure and costs without compromising clinical efficacy compared to traditional 3-drug regimens used for the treatment of HIV. We report the results of a budget impact analysis that estimates the potential economic impact of introducing DTG/3TC in the US.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
